National Center for Immunization and Respiratory Diseases

Adult and Influenza Vaccination Coverage Update

Carla Black, PhD
Immunization Services Division
National Center for Immunization and Respiratory Diseases

NAIIS

May 13, 2025

Outline

- **Adult respiratory virus vaccination coverage (2024–25 season preliminary data)**
- **Child influenza vaccination coverage (2024–25 season preliminary data)**
- **Adult non-respiratory virus vaccination coverage**

Respiratory Virus Vaccination Coverage Update, 2024-25 Season

National Immunization Survey-Adult COVID Module (NIS-ACM) Methods

- **The NIS-ACM is a random-digit-dial cellular telephone survey of adults age ≥18 years in the U.S.**
- **Respondents are sampled within all 50 states, District of Columbia, five local jurisdictions (Bexar County TX, Chicago IL, Houston TX, New York City NY, and Philadelphia County PA), Guam, Puerto Rico and the U.S. Virgin Islands.**
- **Data are weighted to represent the non-institutionalized U.S. population.**
  - Estimates from the NIS-ACM may differ from estimates based on other data sources, and are subject to errors resulting from incomplete sample frame (exclusion of households without cell phones), selection bias (survey respondents may be more likely to be vaccinated than non-respondents), and errors in self-reported vaccination status. Estimates are weighted to selected sociodemographic characteristics of the U.S. population to reduce possible bias from incomplete sample frame and selection bias.
- **All responses are self-reported.**
- **Additional information is available at About the National Immunization Surveys.**

Influenza Vaccination Coverage



Influenza vaccination coverage among adults ≥18 years, 2023–24 and 2024–25 seasons, NIS-ACM



April 27, 2024: 47.4%
April 26, 2025: 46.7%

Influenza vaccination status and intent among adults age ≥18 years by demographics, NIS-ACM, April 21–27, 2025 (n = 8,861)




Influenza Vaccination Coverage Among Children 6 months–17 years, United States, 2010–2024
Percentage Vaccinated
100
80
60
40
20
0
51.0
51.5
56.6
58.9
59.3
59.3
59.0
57.9
62.6
63.7
58.6
57.8
57.4
55.4
2010–11
2011–12
2012–13
2013–14
2014–15
2015–16
2016–17
2017–18
2018–19
2019–20
2020–21
2021–22
2022–23
2023–24
Flu Season
Data Source: National Immunization Survey-Flu (NIS-Flu)
Error bars represent 95% confidence intervals around the estimates.


Influenza vaccination coverage among children 6 months–17 years, 2023–24 and 2024–25 seasons, NIS-Flu
2024-2025,
2023-2024,
Percent Vaccinated
100%
80%
60%
40%
20%
0%
Healthy People Target: 70%
April 27, 2024: 53.4%
April 26, 2025: 49.2%
10/5/2024
10/12/2024
10/19/2024
10/26/2024
11/2/2024
11/9/2024
11/16/2024
11/23/2024
11/30/2024
12/7/2024
12/14/2024
12/21/2024
12/28/2024
1/4/2025
1/11/2025
1/18/2025
1/25/2025
2/1/2025
2/8/2025
2/15/2025
2/22/2025
3/1/2025
3/8/2025
3/15/2025
3/22/2025
3/29/2025
4/5/2025
4/12/2025
4/19/2025
4/26/2025
5/3/2025
5/10/2025
5/17/2025
5/24/2025
Current Season Week Ending Date

Influenza vaccination status and parental intent among children 6 months–17 years by demographics, NIS-Flu, April 27–May 3, 2025 (n = 4,002)



Influenza vaccination coverage, by season and urbanicity, children 6 months–17 years, NIS-Flu, United States, through April each season



Influenza vaccination coverage, by season and race and ethnicity, Children 6 months–17 years, NIS-Flu, United States, through April of each season



COVID-19 Vaccination Coverage

COVID-19 Vaccination Coverage Among Adults ≥18 Years, 2023–24 & 2024–25 Seasons



April 27, 2024: 21.6%
April 26, 2025: 23.0%

COVID-19 vaccination status and intent among adults age ≥18 years by demographics, NIS-ACM, April 21–27, 2025 (n = 8,857)



RSV Vaccination Coverage

Percentage of adults ≥75 years and 60–74 years with high-risk conditions ever vaccinated with RSV vaccine, 2024–25, NIS-ACM



COVID-19 vaccination status and intent among adults age ≥75 years by demographics, NIS-ACM, April 21–27, 2025 (n = 1,009)



***Any of the following conditions: chronic lung disease, diabetes with insulin use, heart conditions, immunocompromised, solid organ or blood stem cell transplant, cancer, liver disease, sickle cell disease or thalassemia, or lives in a nursing home.
NA: estimate not reported because denominator is <30; AI/AN: American Indian or Alaska Native; NH/OPI: Native Hawaiian or Other Pacific Islander.

COVID-19 vaccination status and intent among adults age 60–74 years (high risk***) by demographics, NIS-ACM, April 21–27, 2025 (n = 610)



***Any of the following conditions: chronic lung disease, diabetes with insulin use, heart conditions, immunocompromised, solid organ or blood stem cell transplant, cancer, liver disease, sickle cell disease or thalassemia, or lives in a nursing home.
NA: estimate not reported because denominator is <30; AI/AN: American Indian or Alaska Native; NH/OPI: Native Hawaiian or Other Pacific Islander.

Attitudes and Beliefs Related to Respiratory Viruses and Vaccination

Omnibus Survey Methods

- **Data are collected through the IPSOS KnowledgePanel and NORC AmeriSpeak Omnibus Surveys, which use probability-based panels to survey a nationally representative sample of U.S. adults ≥18 years of age on a set monthly schedule.**
- **CDC fields questions about vaccination status, intent, knowledge, attitudes, beliefs, and behaviors on each survey for 2 waves each month, for a combined sample size of ~4,000 per month.**
- **Data were weighted to represent the non-institutionalized U.S. population and mitigate possible non-response bias. All responses are self-reported.**

"Did/Do you have any of the following concerns or issues about getting a 2024-2025 flu vaccine?" Most commonly reported options* among adults aged ≥18 years, by vaccine receipt and intent, Omnibus Surveys, February 6-24, 2025



*Other response options not shown in the figure include: cost, could not find a vaccine, not eligible/unsure if eligible, allergic/other medical reason, got sick from past vaccine or know someone who did, have enough immunity, did not want to get with another vaccine and other.

"Did/Do you have any of the following concerns or issues about getting a 2024-2025 COVID-19 vaccine?" Most commonly reported options* among adults aged ≥18 years, by vaccine receipt and intent, Omnibus Surveys, February 6-24, 2025



*Other response options not shown in the figure include: cost, could not find a vaccine, not eligible/unsure if eligible, allergic/other medical reason, got sick from past vaccine or know someone who did, have enough immunity, vaccine is too new and other.

"Did/Do you have any of the following concerns or issues about getting the RSV vaccine?" Most commonly reported options* among adults aged 60-74 years with high-risk health conditions† or ≥75 years, by vaccine receipt and intent, Omnibus Surveys, February 6-24, 2025



*Other response options not shown in the figure include: cost, could not find a vaccine, not eligible/unsure if eligible, allergic/other medical reason, got sick from past vaccine or know someone who did, have enough immunity, effectiveness, do not trust government, did not want to get with another vaccine and other.
†High-risk health conditions include chronic lung disease, heart conditions, solid organ or blood stem cell transplant, cancer (excluding basal cell carcinoma and squamous cell carcinoma), diabetes, liver disease, sickle cell disease or thalassemia, BMI≥40, and immunocompromised state.

Adult Vaccination Coverage, National Health Interview Survey

National Health Interview Survey (NHIS) methods

- **Continuous, cross-sectional national household survey of the noninstitutionalized U.S. civilian population**
- **Analysis includes interviews conducted January–December in calendar years 2018 –2023:**
  - Some vaccines are assessed on rotational basis
    - Tetanus every 3 years
    - Hepatitis B every 2/3 years
  - Sample size 27,376 adults aged ≥19 years in 2022; 29,522 in 2023
  - 2022 NHIS response rate 47.7%; 2023 response rate 47.0%
- **Data were weighted to produce national vaccination coverage estimates**
- **T-tests were used for comparisons between data years and groups**

Estimated proportion of adults aged ≥19 years who received selected vaccines, by age group and risk status — National Health Interview Survey, United States, 2018–2023



† Received Td or Tdap in past 10 years. Tetanus vaccination is assessed in the NHIS on a 3-year rotation.
§ High risk conditions include diabetes, emphysema, chronic obstructive pulmonary disease, coronary heart disease, angina, heart attack, or other heart condition, cancer (excluding nonmelanoma skin cancer), asthma in past 12 months, chronic kidney or liver disease (not assessed in 2019 and 2022), and current smoker.
*Two doses of recombinant zoster vaccine (RZV) have been recommended for all adults ≥50 years since 2018.

Hepatitis B vaccination coverage among adults born before 1991, National Health Interview Survey, 2018-2023



*Age ≥27 years in 2018, ≥30 years in 2021, and ≥32 years in 2023

Hepatitis B vaccination coverage among adults born before 1991*, with and without risk factors†, National Health Interview Survey, 2018-2023



*Age ≥27 years in 2018, ≥30 years in 2021, and ≥32 years in 2023
†Travel, history of hepatitis, live with someone with hepatitis

Vaccination coverage estimates using an age-appropriate composite* adult vaccination quality measure, by age group — National Health Interview Survey, United States, 2022



*A composite estimate of overall vaccination coverage among adults aged ≥19 years who received the selected vaccines recommended for their age group: for adults aged 19–49 years, (influenza) AND Td or Tdap vaccines; for adults aged 50–64 years, (influenza), Td or Tdap, AND herpes zoster vaccines; for adults aged ≥65 years, (influenza), Td or Tdap, herpes zoster, AND pneumococcal vaccines. Estimates for each age group include adults who have received all of the selected vaccines for that specific age group.

Vaccination coverage estimates among adults ≥19 years using an age-appropriate composite* adult vaccination quality measure, by race and ethnicity — National Health Interview Survey, United States, 2022



*A composite estimate of overall vaccination coverage among adults aged ≥19 years who received the selected vaccines recommended for their age group: for adults aged 19–49 years, (influenza) AND Td or Tdap vaccines; for adults aged 50–64 years, (influenza), Td or Tdap, AND herpes zoster vaccines; for adults aged ≥65 years, (influenza), Td or Tdap, herpes zoster, AND pneumococcal vaccines. Estimates for each age group include adults who have received all of the selected vaccines for that specific age group.
§p<0.05 compared with Non-Hispanic White.

Summary

- **Preliminary vaccination coverage among adults for the 2024–25 season is 47% for influenza, 23% for COVID-19, and 38% and 48% for RSV (60-74 and 75+, respectively)**
- **Consistent declines in influenza vaccination coverage since the 2019-20 season among children**
  - Largest decreases seen among White and rural children
- **Coverage for other adult vaccines remains low**
  - 22.8% of adults ≥19 years have received age-appropriate doses of influenza, tetanus, zoster, and pneumococcal vaccine
  - Disparities by race and ethnicity persist
- **Pneumococcal vaccination coverage among adults ≥65 years decreased from 67.5% in 2020 to 64.0% in 2022**
  - Remained similar in 2023
- **No evidence of an increase in Hepatitis B vaccination coverage since the universal recommendation in 2022**

Acknowledgements

- **Kayla Calhoun**
- **Mei-Chuan Hung**
- **Anurag Jain**
- **Katherine Kahn**
- **Jennifer Kriss**
- **Peng-jun Lu**
- **Suchita Patel**
- **Hilda Razzaghi**
- **Tammy Santibanez**
- **Susanne Schorpp**
- **Jim Singleton**
- **Anup Srivastav**
- **Tianyi Zhou**

Thank you!
cblack2@cdc.gov

For more information visit: VaxView Vaccination Coverage | Vaccines & Immunizations | CDC

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

Back-up slides

Concerns about getting a COVID-19 vaccine* among adults ≥18 years, Omnibus Surveys, November 30-December 21, 2023 vs. December 5-30, 2024



*Response options shown are limited to those that were similar across years, but exact wording differed. For 2023, options related to specific serious side effects were combined to be comparable to 2024. For 2024, distrust in the government and pharmaceutical companies were two separate options, which were combined to be comparable to 2023.

Concerns about getting an influenza vaccine* among adults ≥18 years, Omnibus Surveys, November 30-December 21, 2023 vs. December 5-30, 2024



*Response options shown are limited to those that were similar across years, but exact wording differed. For 2024, options related to mild and serious or unknown side effects were combined to be comparable to 2023. Also, for 2024, distrust in the government and pharmaceutical companies were two separate options, which were combined to be comparable to 2023.

Concerns about getting a RSV vaccine* among adults aged 60-74 years with high-risk health conditions† or ≥75 years, Omnibus Surveys, November 30-December 21, 2023, and December 5-30, 2024



*Response options shown are limited to those that were similar across years, but exact wording differed. For 2023, separate options for no provider recommendation and provider recommended against vaccination were combined to be comparable to 2024. For 2024, options related to mild and serious or unknown side effects were combined to be comparable to 2023. Also, for 2024, distrust in the government and pharmaceutical companies were two separate options, which were combined to be comparable to 2023.

†High-risk health conditions include chronic lung disease, heart conditions, solid organ or blood stem cell transplant, cancer (excluding basal cell carcinoma and squamous cell carcinoma), diabetes, liver disease, sickle cell disease or thalassemia, BMI≥40, and immunocompromised state.